Orthofix Medical Inc. (NASDAQ:OFIX) Receives Consensus Rating of “Moderate Buy” from Analysts

Orthofix Medical Inc. (NASDAQ:OFIX) has received a consensus recommendation of “Moderate Buy” from the five research firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $23.33.

A number of research firms recently issued reports on OFIX. StockNews.com upgraded Orthofix Medical from a “hold” rating to a “buy” rating in a report on Friday, January 31st. Canaccord Genuity Group initiated coverage on Orthofix Medical in a report on Wednesday, January 22nd. They set a “buy” rating and a $24.00 price target for the company. Roth Mkm reaffirmed a “buy” rating and set a $22.00 price target (up from $20.00) on shares of Orthofix Medical in a report on Friday, November 8th. Finally, Stifel Nicolaus raised Orthofix Medical from a “hold” rating to a “buy” rating and lifted their price target for the stock from $18.00 to $24.00 in a report on Friday, November 8th.

Orthofix Medical Trading Up 1.6 %

NASDAQ:OFIX opened at $18.61 on Friday. The firm has a market cap of $711.09 million, a PE ratio of -5.95 and a beta of 1.10. The stock has a fifty day moving average price of $17.93 and a 200 day moving average price of $17.24. Orthofix Medical has a 12-month low of $12.08 and a 12-month high of $20.73. The company has a current ratio of 2.39, a quick ratio of 1.11 and a debt-to-equity ratio of 0.25.

Insider Activity

In other news, CFO Julie Andrews sold 4,655 shares of the business’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $17.89, for a total value of $83,277.95. Following the completion of the sale, the chief financial officer now directly owns 28,312 shares of the company’s stock, valued at approximately $506,501.68. The trade was a 14.12 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Massimo Calafiore sold 9,203 shares of the business’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $17.14, for a total value of $157,739.42. Following the completion of the sale, the chief executive officer now directly owns 124,151 shares of the company’s stock, valued at $2,127,948.14. The trade was a 6.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 25,442 shares of company stock valued at $436,883. Insiders own 2.60% of the company’s stock.

Institutional Trading of Orthofix Medical

Institutional investors and hedge funds have recently made changes to their positions in the company. R Squared Ltd purchased a new stake in shares of Orthofix Medical in the 4th quarter valued at about $50,000. KLP Kapitalforvaltning AS acquired a new position in Orthofix Medical in the 4th quarter valued at about $112,000. Tower Research Capital LLC TRC increased its position in Orthofix Medical by 120.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,458 shares of the medical device company’s stock valued at $148,000 after acquiring an additional 4,627 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Orthofix Medical by 5.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,994 shares of the medical device company’s stock valued at $156,000 after acquiring an additional 559 shares during the period. Finally, Assenagon Asset Management S.A. acquired a new position in Orthofix Medical in the 3rd quarter valued at about $216,000. 89.76% of the stock is owned by hedge funds and other institutional investors.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.